# Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)

> **NCT01394354** · PHASE1,PHASE2 · COMPLETED · sponsor: **University Hospital Freiburg** · enrollment: 34 (actual)

## Conditions studied

- Multiple Myeloma in Relapse

## Interventions

- **DRUG:** Vorinostat
- **DRUG:** Bortezomib
- **DRUG:** Doxorubicin
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT01394354
- **Lead sponsor:** University Hospital Freiburg
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2016-04-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01394354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01394354, "Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01394354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*